Beam Therapeutics

Beam Therapeutics is a biotechnology company located in Cambridge, Massachusetts, founded in 2017. The company specializes in gene therapies and genome editing, particularly through its innovative base editing technologies. Co-founded by notable scientists in the CRISPR field, Beam Therapeutics is dedicated to developing precision genetic medicines aimed at treating serious diseases such as sickle cell disease, T-cell cancers, glycogen storage disease 1a, and Alpha-1 antitrypsin deficiency. The company’s pipeline includes investigational products like BEAM-101, which targets sickle cell disease, along with other products focused on genetic disorders. Beam Therapeutics employs various genome-editing tools, including cytosine and adenine base editors, to provide precise modifications to DNA and RNA. The company is publicly traded on NASDAQ under the ticker symbol BEAM and has raised significant funding to support its research and development efforts. With a growing team of around 483 employees, Beam Therapeutics is committed to delivering lifelong cures to patients through its cutting-edge science and collaborative partnerships.